Praveen Bommareddy, MS, RLAT, serves as the Senior Director of Translational Research at Replimune, where he leverages over 15 years of experience in basic and translational research, with a particular focus on immune oncology. His expertise lies in the innovative application of oncolytic viruses, innate...
Praveen Bommareddy, MS, RLAT, serves as the Senior Director of Translational Research at Replimune, where he leverages over 15 years of experience in basic and translational research, with a particular focus on immune oncology. His expertise lies in the innovative application of oncolytic viruses, innate immune agonists, cytokines, and T cell co-stimulation molecules as immune-modulatory agents. Praveen is instrumental in developing cutting-edge platform ideas that drive R&D activities, facilitating the progression of lead candidates from Investigational New Drug (IND) applications to late-stage development across major solid tumor franchises.
At Replimune, Praveen leads key projects that explore combination immunotherapy approaches, aiming to enhance therapeutic efficacy and improve patient outcomes. His extensive knowledge in assay development, target validation, and molecular oncology enables him to design robust experimental frameworks that assess the effectiveness of novel immunotherapeutic strategies. His proficiency with transgenic mice models and immunostaining techniques further enriches his research, allowing for detailed investigations into the mechanisms of T cell killing and the tumor microenvironment.
A collaborative team player, Praveen fosters a culture of innovation and knowledge sharing within his team, ensuring that diverse perspectives contribute to the advancement of translational research initiatives. His commitment to bridging the gap between laboratory discoveries and clinical applications positions him as a key contributor to Replimune’s mission of developing transformative therapies for cancer patients. With a strong foundation in immunology and oncology, Praveen continues to push the boundaries of what is possible in the field of immune-oncology, driving forward the next generation of cancer treatments.
